allopurinol / Generic mfg. - LARVOL DELTA

GAPS IN CHRONIC AND ACUTE GOUT CARE: REAL-WORLD DATA FROM AN ELECTRONIC HEALTH RECORD-BASED REGISTER (EULAR 2025) - "Use of urate-lowering therapy (ULT)—allopurinol, febuxostat, probenecid, lesinurad, or rasburicase—was evaluated during the in- or outpatient encounter where tophi were documented, as well as at previous and subsequent visits...Use of anti-inflammatory drugs (NSAIDs, colchicine, IL-1 inhibitor, or glucocorticoids) was assessed during hospitalization or within ±2 weeks of a joint aspiration or flare documentation... The prescription of ULT in patients with tophus is suboptimal. Furthermore, a significant proportion of patients who were previously treated did not receive ongoing therapy. Many patients with acute gout flares do not receive anti-inflammatory treatment, potentially resulting in prolonged pain, extended hospital stays, and the risk of major adverse cardiac event."

Clinical • Real-world • Real-world evidence • Gout • Inflammatory Arthritis • Pain • Rheumatology

HOW FAST CAN YOU REACH THE SERUM URATE TARGET DURING INTENSIVE URATE LOWERING THERAPY IN GOUT (EULAR 2025) - "At year 1 mean allopurinol (SD) dose was 289 (120) mg, and 12.5% of patients had switched to febuxostat with a mean (SD) dose of 59 (24) mg. Patients with gout who are treated with internationally recommended intensive ULT reached the treatment target after median 2 months, or after 3 months if initial sUA >480 µmol/L. Only about 5% of patients did not achieve the treatment target at least once during one year with intensive ULT. Our findings indicate fast and effective ULT and support the treat-to-target principle in gout."

Gout • Inflammatory Arthritis • Rheumatology

EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS PLUS URATE-LOWERING DRUGS IN PATIENTS WITH GOUT: DATA FROM A SINGLE-CENTER SPECIALISED CLINIC (EULAR 2025) - "As ULD, 66.7% (n=30) of patients were treated with allopurinol, 28.9% (n=13) with febuxostat, and 4.4% (n=2) with benzbromarone. Regarding the SGLT2I, 58.7% (n=27) received dapagliflozin, 30.4% (n=14) empagliflozin, and 10.9% (n=5) canagliflozin... The combination of SGLT2I and ULD in patients with gout in clinical practice achieved significant SU level reductions and targets of SU <6 and <5 mg/dL. A trend towards a lower dosage requirement of allopurinol was noted, in addition to a reduced use of diuretics. These promising results require confirmation by further intervention studies."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Gout • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • CRP

GOUT CHARACTERISTICS, COMORBIDITIES AND MANAGEMENT IN A LONG PRIMARY CARE DATABASE FROM CATALONIA: THE GotAP STUDY (EULAR 2025) - "The mean duration of treatment with allopurinol was 111.50 [25.00; 208.00] days, whereas for febuxostat, it was 179.00 [56.00; 546.00] days. The majority of Catalonian patients with gout have cardiovascular comorbidities. Most of the patients are undertreated and have a poor adherence to ULT. Being a female, starting of ULT after diagnose, using febuxostat, using high doses of alopurinol and having a greater MPR is associated to a better control of gout."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hypertension • Immunology • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus • Vascular Neurology • BMI1

FOOT AND ANKLE INVOLVEMENT IN GOUT: CLINICAL, RADIOLOGICAL, AND FUNCTIONAL OUTCOMES FROM A FIVE-YEAR STUDY IN A TERTIARY HOSPITAL IN SOUTHERN TUNISIA (EULAR 2025) - "Allopurinol was prescribed as the first-line urate-lowering therapy in 84.9% of cases, with gradually increasing doses, initiated after acute attacks and combined with colchicine at the start. Our findings emphasize the high prevalence and significant impact of foot and ankle involvement in gout. Ultrasound proved valuable for early detection, even in asymptomatic stages. Regular assessment, early diagnosis, and appropriate management are essential to improve patient outcomes and quality of life."

Clinical • Cardiovascular • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Orthopedics • Osteoarthritis • Pain • Rheumatology

SAP-001, A First –in-Class Compound Targeting a Renal Urate Transporter, Shows Potent Serum Urate-Lowering Effects and Favorable Safety Profile in a US Phase 2b Study in Patients with Refractory Gout with or without Palpable Tophi (EULAR 2025) - "The majority of the subjects were male, obese, and on background SOC treatment (more than 90% with either 100 mg, or 300 mg allopurinol for ≥3 months, and with sUA above 7 mg/dL during screening in all patients). Among patients exposed to study drug, SAP-001 demonstrated robust, sustained urate-lowering effect in refractory gout patients with or without palpable tophi. A first in class inhibitor of a distinct renal urate transporter, SAP-001 may offer a mechanistically novel, effective and safe oral ULT drug for difficult- to-treat gout populations."

Clinical • Late-breaking abstract • P2b data • Anemia • Cardiovascular • Gout • Hematological Disorders • Inflammatory Arthritis • Nephrology • Obesity • Pain • Renal Disease • Rheumatology

Treating gout to target serum urate improves health-related quality of life and utility over five years (EULAR 2025) - " In the prospective NOR-Gout study, 211 patients with confirmed gout were included to a treat to target strategy with urate lowering therapy with allopurinol or febuxostat. Following a treat-to-target strategy, HRQoL values increased with 0.07 and 0.098 over a period of five years. Although no minimal clinical important difference has been established for these instruments, a value of 0.03 has been suggested. Compared to the size of improvements often seem in health economic evaluations, with a median incremental gain was 0.06 across all types of interventions and diseases [5], the improvements seen in these gout patients represents quite a large health gain."

Clinical • HEOR • Gout • Inflammatory Arthritis • Pain • Rheumatology

Predicting the risk of severe cutaneous adverse reactions in new allopurinol users: development and validation of a multivariable prediction model using linked primary care, hospitalisation, and mortality data from England (EULAR 2025) - "We developed and validated a risk-prediction model that uses readily available clinical information to predict the risk of SCARs due to allopurinol. It had net-benefit across a range of risk and can be used to make an informed choice of ULT. Further research is needed to validate the model outside of the UK."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Dermatology • Heart Failure • Nephrology • Renal Disease • Steven-Johnson Syndrome • HLA-B

Sustained Efficacy of Pozdeutinurad (AR882): Long-Term Treatment Effect of a Novel and Selective URAT1 Inhibitor in Patients with Chronic Gouty Arthritis (EULAR 2025) - "Background: Pozdeutinurad (AR882) is a novel and selective URAT1 inhibitor currently in Phase 3 clinical stage development for the treatment of gout and tophaceous gout. The long-term treatment of pozdeutinurad in patients with tophaceous gout demonstrated sustained and efficacious sUA lowering and continued tophus resolution from the initial 6 months of treatment through 18 months of treatment. Pozdeutinurad alone or combination may provide an effective treatment option for patients with chronic gout, including those with clinically visible tophi that are difficult to treat. Pozdeutinurad maintained high response rates to treatment up to 18 months of treatment Pozdeutinurad showed high response rates of complete resolution in both target and non-target tophi up to 18 months *subjects were originally assigned allopurinol treatment at baseline with pozdeutinurad 75 mg added after 6 months; ext: extension; mo: month"

Clinical • Gout • Immunology • Inflammatory Arthritis • Rheumatology

Allopurinol associated cardiovascular risk and protective effect of colchicine in gout patients: a Dutch nationwide pharmaco-epidemiologic cohort study. (EULAR 2025) - "A CV event was defined as a new dispensed prescription for a platelet aggregation inhibitor (clopidogrel, prasugrel, ticagrelor or dipyridamole). After allopurinol start – especially the first 30 to 90 days - there is a dose-dependent increase in the risk of cardiovascular risk, which is fully countered by concomitant colchicine use. Discontinuation of allopurinol does not lead to a relevant increase in cardiovascular event risk. Concomitant use of colchicine or slower dose escalation of allopurinol seems prudent to decrease the risk of CV events in gout patients starting allopurinol."

Clinical • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hypertension • Inflammatory Arthritis • Rheumatology

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists (EULAR 2025) - "Patients were currently or most recently treated with allopurinol (72%) or febuxostat (25%), with 5% on uricase treatment. There were differences in dosing and the frequency of monitoring patients sUA levels, with rheumatologists being significantly more likely to utilize higher doses and monitor sUA levels more frequently. Additionally, patients managed by nephrologists had a higher disease burden (i.e. higher likelihood of presenting with a renal disease, and significantly higher rates of hospitalization, and hospital length of stay)."

Chronic Kidney Disease • Gout • Inflammatory Arthritis • Musculoskeletal Pain • Nephrology • Pain • Rheumatology

REMONIT GOUT FEASIBILITY STUDY: A SELF-MANAGEMENT APP IN A TREAT-TO-TARGET GOUT CARE APPROACH (EULAR 2025) - "If intolerance to allopurinol, febuxostat was an alternative...Colchicine, eterocoxib and prednisolone were used as flare medication without prophylaxis in one patient each... The overall feasibility of Urika and the study logistics were satisfactory with >70% of the predefined feasibility criteria reached. The study results will be used to further improve hUrika functions and study logistics, but demonstrated that Urika is suitable to be tested in a future large clinical investigation of a digital treat-to-target gout care approach."

Gout • Inflammatory Arthritis • Rheumatology

Colchicine concentrations and relationship with colchicine efficacy and adverse events; post-hoc analysis of a randomised clinical trial of colchicine for gout flare prophylaxis (EULAR 2025) - " Post hoc analyses were undertaken using data from a 12-month RCT involving 200 people with gout which compared low-dose colchicine to placebo for the first six months while starting allopurinol, with a further 6-month follow-up. Trough or peak colchicine concentrations do not associate with gout flare prophylaxis efficacy. There is no consistent relationship between colchicine concentrations and colchicine-specific adverse events. Although colchicine concentrations increase with concomitant statin use, this does not result in muscle adverse events."

Adverse events • Clinical • Retrospective data • Gout • Inflammatory Arthritis • Rheumatology

EFFICACY OF A ONE-STOP PHARMACIST-, DIETITIAN- AND NURSE-STAFFED GOUT CLINIC VERSUS GENERAL CARE FOR GOUT: A RETROSPECTIVE OBSERVATIONAL STUDY (EULAR 2025) - "For the ULT used for gout treatment, majority of the patients (71.5%) were on Allopurinol, whereas 27.5% of patients were on Febuxostat and only 1% of the patients were on Probenecid...Notably, nearly half of these patients had CKD ≥ Stage 3, necessitating renal-adjusted doses of ULT and colchicine, alongside patient education on the cautious use of NSAIDs to prevent its complications and early referral to Nephrology team for CKD retardation. This study demonstrates the efficacy of the One-stop Gout Clinic in achieving target sUA level of <360 µmol/L within a year. Additionally, it showed improved patient compliance and optimization of ULT dosing compared to the General Clinic. The convenience of having allied health input in one setting together with scheduled drug titration schedules were the likely reasons for the success of this program."

Observational data • Retrospective data • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hypertension • Inflammatory Arthritis • Nephrology • Obesity • Renal Calculi • Renal Disease • Rheumatology

Ruzinurad for hyperuricemia associated with primary gout: a multicenter, randomized, double-blind, active-controlled, phase 3 study (EULAR 2025) - P3 | "The URAT1 inhibitor ruzinurad demonstrated superior sUA lowering effect over allopurinol, along with a well-tolerated safety profile, in patients with hyperuricemia associated with primary gout."

Clinical • P3 data • Gout • Infectious Disease • Inflammatory Arthritis • Respiratory Diseases • Rheumatology

Safety and Tolerability of Pozdeutinurad (AR882) Treatment following Long-term Dosing in Patients with Chronic Gouty Arthritis and Subcutaneous Tophi (EULAR 2025) - "There were 4 serious adverse events (3 patients) reported, but none of them were considered related to pozdeutinurad, allopurinol, or therapy for flare prophylaxis, such as colchicine. The long-term treatment of pozdeutinurad alone or in combination with allopurinol for the treatment of tophaceous gout patients was well tolerated, showed comparable safety profile, and better efficacy to allopurinol alone. These results support pozdeutinurad as a safe option for the treatment of patients with gout, including those with both clinically visible and subclinical crystal deposition. Most frequently-occurring (≥ 2 patients in any treatment group) treatment-emergent adverse events within 18 months of treatment AR50: pozdeutinurad (AR882) 50 mg; AR75: pozdeutinurad (AR882) 75 mg; ALLO: allopurinol; mo: month Elevations of serum creatine or liver functions within 18 months of treatment AR50: pozdeutinurad (AR882) 50 mg; AR75: pozdeutinurad (AR882) 75 mg; ALLO: allopurinol; mo: month"

Clinical • Gout • Immunology • Inflammatory Arthritis • Nephrology • Renal Calculi • Rheumatology

Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial (EULAR 2025) - P2 | "ULT options included oral allopurinol 100 mg/day, febuxostat 40 mg/day, or benzbromarone 50 mg/day. Genakumab demonstrated efficacy as a prophylaxis against acute gout flares in adults with gout initiating ULT and was generally well-tolerated. A single dose of genakumab 100 mg or 200 mg reduced the average number of acute gout flares per patient and shortened flare duration over 12 weeks, with a safety profile similar to daily colchicine. Notably, in the genakumab 200 mg group, gout flares were not observed for the entire 12-week period, a finding that will be further investigated in larger sample populations."

Clinical • P2 data • Dyslipidemia • Gout • Hypertriglyceridemia • Inflammatory Arthritis • Pain • Rheumatology • IL1B

Unveiling the therapeutic benefits of black chokeberry (Aronia melanocarpa) in alleviating hyperuricemia in mice. (PubMed, Front Nutr) - "Black chokeberry effectively increased the glutathione levels in hyperuricemic mice and reduced malondialdehyde levels, as well as significantly inhibiting adenosine deaminase activity. Its efficacy is comparable to that of the marketed drug allopurinol, underscoring the potential of black chokeberry as a functional product for uric acid reduction."

Journal • Preclinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy. (PubMed, Pharmaceuticals (Basel)) - " The combination of ALP and DSF provided superior anti-inflammatory and urate-lowering effects compared to individual treatments. These findings support the potential of disulfiram as an adjunct to conventional ULTs in gout management through dual modulation of urate metabolism and inflammasome-driven inflammation."

Journal • Preclinical • Gout • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • IL1B • IL6 • NLRP3 • TNFA

Treatment of Leishmania infantum Infections in Dogs. (PubMed, Microorganisms) - "Since most of the drugs used in dogs are also applied in human medicine, the prevention of treatment-induced drug-resistant Leishmania strains is a major one-health concern. This review article provides an overview of current treatment options for Leishmania-infected dogs with allopurinol, meglumine antimoniate, and miltefosine, related adverse effects, and drug resistance potential."

Journal • Review • Infectious Disease

Drug Toxicity and My Dad's Ethnicity. (PubMed, Ann Fam Med) - "My Korean-American father experienced a severe drug eruption after receiving allopurinol for gout...Given the complexity of the discourse around engaging race and ethnicity in medical practice, my father's experience led me to contemplate the current context of eliminating race from clinical decision making to address historical and ongoing injustices. Upon this reflection, I advocate for the separation of race and ethnicity to appropriately consider ethnicity when it may support quality and safety of care for all patients."

Journal • Gout • Inflammatory Arthritis • Rheumatology

The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis. (PubMed, Br J Clin Pharmacol) - "Switching to LDTA or TG therapy in shunting IBD patients resulted in favourable alterations in thiopurine metabolism. However, LDTA appears to have a slightly less favourable metabolite profile, with some residual 6-MMPR formation and fewer patients achieving normal 6-TGN levels compared to TG. Given the challenges associated with achieving optimal thiopurine metabolite levels with LDTA and the need for closer monitoring of 6-TGN levels, TG appears a more suitable option for thiopurine shunting IBD patients."

Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Integrating natural products with modern medicine in the treatment of gouty arthritis: a review. (PubMed, Inflammopharmacology) - "To reduce circulating urate levels, commonly used drugs include allopurinol and febuxostat. A rising number of researchers document that traditional medications can reduce serum urate levels. This article is intended to trace which herbal remedies could alleviate hyperuricemia, as well as their mechanism of actions."

Journal • Review • Gout • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatology

Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations. (PubMed, Arthritis Rheumatol) - "In these target trial emulations of patients with gout starting allopurinol, NSAID prophylaxis was associated with a higher risk of MACE than colchicine or no prophylaxis, suggesting the avoidance of NSAID for gout flare prophylaxis."

Journal • Cardiovascular • Gout • Inflammatory Arthritis • Myocardial Infarction • Rheumatology

The binding of phenobarbital, phenytoin, and dapsone to HLA-B*13:01 differs from that of allopurinol to HLA-B*13:02 (SID 2025) - "The common binding modes of HLA*13:01 and phenobarbital, phenitoin, and dapsone suggest the hot spots of their interaction with, and the key residues for their binding selectivity to, HLA-B*13:01."

Late-breaking abstract • HLA-B